PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs TRVN's -27.28%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Below half of TRVN's -27.28%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
Below half of TRVN's -23.29%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.34%
≥ 1.5x TRVN's -3.35%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Below half of TRVN's 8.16%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Below half of TRVN's -19.60%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-4.95%
Less than half of TRVN's -47.04%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Less than half of TRVN's 2.90%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
≥ 1.5x TRVN's -100.00%. David Dodd sees stronger subscription/prepayment demand.
-89.58%
50-75% of TRVN's -160.82%. Bruce Berkowitz notes a more controlled liability line.
-16.33%
Above 1.5x TRVN's -2.83%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x TRVN's -3.38%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Above 1.5x TRVN's -3.05%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
0.5-0.75x TRVN's -3.32%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Similar yoy to TRVN's 100.00%. Walter Schloss sees parallel comprehensive income changes.
-100.00%
Less than half of TRVN's 100.00%. David Dodd notes simpler yoy equity changes vs. competitor.
-6.40%
Below half TRVN's -23.57%. Michael Burry sees potential underperformance in building shareholder capital.
-7.25%
Below half TRVN's -19.60%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Above 1.5x TRVN's -2.68%. Michael Burry sees a major jump. Investigate leverage rationale.
7.35%
Less than half of TRVN's 30.20%. David Dodd sees better deleveraging or stronger cash buildup than competitor.